SPAGNUOLO, ROCCO
 Distribuzione geografica
Continente #
NA - Nord America 1.408
EU - Europa 1.100
AS - Asia 978
SA - Sud America 294
OC - Oceania 45
AF - Africa 22
Continente sconosciuto - Info sul continente non disponibili 5
Totale 3.852
Nazione #
US - Stati Uniti d'America 1.334
IT - Italia 441
SG - Singapore 409
BR - Brasile 231
DE - Germania 220
CN - Cina 154
GB - Regno Unito 125
IN - India 125
FI - Finlandia 108
VN - Vietnam 104
SE - Svezia 50
CA - Canada 45
NL - Olanda 42
AU - Australia 37
AR - Argentina 24
HK - Hong Kong 22
IR - Iran 22
ID - Indonesia 19
KH - Cambogia 18
MX - Messico 16
FR - Francia 14
PL - Polonia 14
RO - Romania 14
MY - Malesia 12
EC - Ecuador 11
TH - Thailandia 11
BD - Bangladesh 10
JP - Giappone 10
AT - Austria 9
CO - Colombia 9
RU - Federazione Russa 9
IQ - Iraq 8
NZ - Nuova Zelanda 8
CL - Cile 7
ES - Italia 7
PK - Pakistan 7
TR - Turchia 7
ET - Etiopia 6
LV - Lettonia 6
CZ - Repubblica Ceca 5
RS - Serbia 5
SA - Arabia Saudita 5
UA - Ucraina 5
YE - Yemen 5
AE - Emirati Arabi Uniti 4
GR - Grecia 4
IE - Irlanda 4
KR - Corea 4
PH - Filippine 4
PY - Paraguay 4
TW - Taiwan 4
UZ - Uzbekistan 4
A2 - ???statistics.table.value.countryCode.A2??? 3
CY - Cipro 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
JM - Giamaica 3
MA - Marocco 3
TN - Tunisia 3
VE - Venezuela 3
ZA - Sudafrica 3
BO - Bolivia 2
CH - Svizzera 2
CU - Cuba 2
EG - Egitto 2
EU - Europa 2
HR - Croazia 2
IL - Israele 2
LT - Lituania 2
MK - Macedonia 2
NO - Norvegia 2
PE - Perù 2
BG - Bulgaria 1
BJ - Benin 1
BW - Botswana 1
BY - Bielorussia 1
BZ - Belize 1
GA - Gabon 1
GD - Grenada 1
HU - Ungheria 1
KE - Kenya 1
KW - Kuwait 1
LB - Libano 1
LC - Santa Lucia 1
MD - Moldavia 1
NG - Nigeria 1
NP - Nepal 1
PT - Portogallo 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 3.852
Città #
Singapore 232
Chandler 191
Munich 176
Dallas 127
Bengaluru 94
Hefei 91
Milan 91
Santa Clara 90
Ashburn 68
Chicago 59
Helsinki 59
London 57
Lawrence 50
Princeton 50
Catanzaro 47
Ho Chi Minh City 45
Turku 41
Boardman 40
São Paulo 28
Rome 26
Council Bluffs 23
Los Angeles 23
New York 23
Wilmington 23
Edinburgh 22
Hong Kong 18
Phnom Penh 18
Des Moines 16
Hanoi 16
Rio de Janeiro 12
Sydney 12
Redwood City 11
Palermo 10
Redmond 10
San Francisco 10
Amsterdam 9
Hamilton 9
Toronto 9
Warsaw 9
Beijing 8
Boston 8
Brooklyn 8
Christchurch 8
Mexico City 8
San Nicola Manfredi 8
Tokyo 8
Adelaide 7
Brisbane 7
Campinas 7
Chennai 7
Florence 7
Hanover 7
Shanghai 7
Fortaleza 6
Guayaquil 6
Jakarta 6
Montreal 6
Naples 6
Norwalk 6
Nuremberg 6
Pattaya 6
Perth 6
Riga 6
Seattle 6
Taranto 6
Bari 5
Brasília 5
Buffalo 5
Campo Bom 5
Catania 5
Collegeville 5
Delhi 5
Guangzhou 5
Horia 5
Hortolândia 5
Jyväskylä 5
Kingston 5
Olomouc 5
Ottawa 5
Phoenix 5
Provo 5
Sanaa 5
Santiago de Cali 5
Stockholm 5
Turin 5
Verona 5
Washington 5
Assago 4
Athens 4
Atlanta 4
Bangkok 4
Belo Horizonte 4
Berlin 4
Bolzano 4
Castellammare di Stabia 4
Cittanova 4
Columbus 4
Curitiba 4
Falkenstein 4
Gdynia 4
Totale 2.284
Nome #
Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome 286
Adverse drug reactions during biologic therapy in inflammatory disease: real life data from the pharmacovigilance project in the Calabria region 230
BETA-GLUCAN, INOSITOL AND DIGESTIVE ENZYMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ASSOCIATED WITH IRRITABLE BOWEL SYNDROME 221
Deregulation of SGK1 in Ulcerative Colitis: A Paradoxical Relationship Between Immune Cells and Colonic Epithelial Cells. 91
Anti interleukin 12/23 in the treatment of erythema nodosum and Crohn disease: A case report. 64
COVID-19 and Inflammatory Bowel Disease: Patient Knowledge and Perceptions in a Single Center Survey 62
The role of gluten-free diet in nonalcoholic fatty liver disease development 61
Acceptability of endoscopic procedures and patients' willingness to repeat them: a single-centre nursing study of influential factors 60
Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome 59
L’epatopatia alcolica: dal danno alla terapia 58
Patient Reported Outcomes come strumento infermieristico nella gestione delle Malattie Infiammatorie Croniche Intestinali (MICI): Sintomi Gastrointestinali e Alterazioni Psicosociali. 58
Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy 55
Biologics for Inflammatory Bowel Disease in Clinical Practice: A Calabria (Southern Italy) Prospective Pharmacovigilance Study 54
COMPARISON BETWEEN DIFFERENT BOWEL PREPARATION REGIMENS FOR COLONOSCOPY: A SINGLE-CENTRE STUDY 52
Evidence for the presence of non-celiac gluten sensitivity in patients with functional gastrointestinal symptoms: Results from a multicenter randomized double-blind placebo-controlled gluten challenge 52
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 52
Effects of a Portfolio-Mediterranean Diet and a Mediterranean Diet with or without a Sterol-Enriched Yogurt in Individuals with Hypercholesterolemia 51
DIAPHRAGMATIC REHABILITATION IN GASTROOESOPHAGEAL REFLUX DISEASE 50
OUTCOME OF ARTHRALGIA IN A SUBGROUP OF INFLAMMATORY BOWEL DISEASE PATIENTS WITH ANTI-TNF-ALPHA. A SINGLE CENTRE STUDY 50
Gastrointestinal Symptoms Impact Psychosocial Function and Quality of Life in Patients with Rheumatoid Arthritis and Spondyloarthritis: A Cross-Sectional Study 49
Safety profile of intravenous iron in inflammatory bowel disease: an up-to-date overview 49
Inborn and acquired risk factors for severe liver disease in Europeans with type 2 diabetes from the UK Biobank 45
Deregulation of SGK1 in Ulcerative Colitis: a paradoxical relationship between immune cells and colonic epithelial cells 43
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study 43
Weight Gain and Liver Steatosis in Patients with Inflammatory Bowel Diseases 43
Psychometric evaluation of an Italian custom 4-item short form of the PROMIS anxiety item bank in immune-mediated inflammatory diseases: An item response theory analysis 43
Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome 42
DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection 42
C-reactive protein induces tissue factor expression and promotes smooth muscle cells and endothelial cell proliferation 42
Knowledge of Diagnostic and Therapeutic Aspects of IBD Among Nurses Working in Digestive Endoscopy: A Nationwide Italian Survey 41
COVID-19 Vaccine Booster Shot Preserves T Cells Immune Response Based on Interferon-Gamma Release Assay in Inflammatory Bowel Disease (IBD) Patients on Anti-TNFα Treatment 40
Nursing issues in enteral nutrition during prone position in critically ill patients: A systematic review of the literature 40
Impact of Nursing Interventions via Telephone and Email on the Quality of Life of Patients with Inflammatory Bowel Disease: Preliminary Results of a Comparative Observational Study 39
Nursing communication as a tool for patient satisfaction. A single hospital survey 39
Nursing-sensitive outcomes in adult inflammatory bowel disease: A systematic review 39
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores 39
Phytomedicines to Target Hepatitis B Virus DNA Replication: Current Limitations and Future Approaches 39
Ulcerative Colitis as an Independent Risk Factor for Hepatic Steatosis 38
The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. 38
Case Report: A Migrating Stitch in a Crohn’s Disease Patient 38
ANGPTL3 Downregulation Increases Intracellular Lipids by Reducing Energy Utilization 37
PNPLA3 148M Carriers with Inflammatory Bowel Diseases Have Higher Susceptibility to Hepatic Steatosis and Higher Liver Enzymes. 37
Adaptation of the European Crohn's Colitis Organisation quality of care standards to Italy: The Italian Group for the study of inflammatory bowel disease consensus 36
The role of Neopterin in cardiovascular disease 36
Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank 35
Exome-wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated with Fatty Liver Disease 35
Effects of listening to music in digestive endoscopy: A prospective intervention study led by nursing 35
Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG-IBD study 35
Use of Metabolic Scores and Lipid Ratios to Predict Metabolic Dysfunction-Associated Steatotic Liver Disease Onset in Patients with Inflammatory Bowel Diseases 34
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study 34
The effects of stress on gut virome: Implications on infectious disease and systemic disorders 34
OBSERVING THE INFLUENCE OF SHAME AND GUILT IN INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW 34
Surgery for a gastric Dieulafoy's lesion reveals an occult bleeding jejunal diverticulum. A case report. 34
Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies 33
Gut Microbiota Profile Changes in Patients with Inflammatory Bowel Disease and Non-Alcoholic Fatty Liver Disease: A Metagenomic Study 33
Effect of excess body weight on the genetic susceptibility to cancer. 33
HIGH DIAGNOSTIC YIELD OF HISTOLOGICAL ANALYSIS OF EUS FINE-NEEDLE ASPIRATION BIOPSY INCLUDED IN FORMALIN WITHOUT ON-SITE CYTOPATHOLOGIC EXAMINATION. A RETROSPECTIVE STUDY 33
Pro-atherothrombotic effects of sigarette smoking in endothelial cells. Protective effects of statins 32
PCSK9 rs11591147 R46L Loss-of-Function Variant Protects Against Liver Damage in Individuals with NAFLD 32
Multifaceted pathogenesis of liver steatosis in inflammatory bowel disease: A systematic review 32
Gut Microbiota in Non-Alcoholic Fatty Liver Disease Patients with Inflammatory Bowel Diseases: A Complex Interplay 32
Measuring Mood and Anxiety Disorders by Patient Reported Outcomes in Inflammatory Bowel Disease: A Literature Review Update 31
Alagille Syndrome and Its Clinical and Laboratory Features: A Case Report 31
Lived Experiences of Patients With Inflammatory Bowel Disease in Italy: A Phenomenological Investigation 31
Satisfaction in Social Roles and Physical Function in Immune-mediated Inflammatory Diseases: A Cross-Sectional Study 30
Switching rate from intravenous to subcutaneous vedolizumab in managing inflammatory bowel diseases is lower than expected 30
Milk thistle, Sylibum marianum 30
W1173 An In Vivo Study to Evaluate {MLCK} Expression in Patients with Inflammatory Bowel Diseases 29
Visualization of Comorbidities in Inflammatory Bowel Diseases through Networks 29
Long-Term Effectiveness and Safety of Ustekinumab in Crohn’s Disease: Results from a Large Real-Life Cohort Study 29
Milk Thistle, Silybum marianum 29
Fatigue and Associated Factors in an Immune-Mediated Inflammatory Disease Population: A Cross-Sectional Study 27
Gastrointestinal symptoms of and psychosocial changes in inflammatory bowel disease: A nursing-led cross-sectional study of patients in clinical remission 27
Use of biosimilars in inflammatory bowel disease: A position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 27
Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study 27
Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study 27
Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study 26
Can dysmetabolic comorbidities carry hepatic fat accumulation in patients with inflammatory bowel diseases? 25
Pyoderma Gangrenosum and inflammatory bowel disease: a combined medical and surgical approach - case report and literature review 25
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning-the IG-IBD LIVE study 24
Change in Diagnosis of Helicobacter pylori Infection in the Treatment-Failure Era 22
Cross talk between liver and adipose tissue: A new role for PNPLA3? 22
Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients with Inflammatory Bowel Diseases: A Pilot Study 21
Impact of diet and gut microbiota changes in the development of hepatocellular carcinoma 21
Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis 21
Esophageal rupture after Heimlich maneuver: a case report and literature review 20
Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study 19
Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study 19
MBOAT7 in liver and extrahepatic diseases 18
Safety, hesitancy of coronavirus disease 2019 vaccination and pandemic burden in patients with inflammatory bowel disease: data of a national study (ESCAPE-IBD) 16
Lack of Seroconversion Following COVID-19 Vaccination Is an Independent Risk Factor for SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: Data from ESCAPE-IBD, an IG-IBD Study 16
Totale 4.002
Categoria #
all - tutte 35.504
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.504


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021185 0 0 0 28 47 17 17 13 41 5 4 13
2021/2022208 7 1 6 41 16 8 9 39 15 35 22 9
2022/2023672 104 52 23 64 56 47 19 73 86 47 64 37
2023/2024552 94 68 49 32 41 94 25 44 22 14 15 54
2024/20251.288 139 41 39 44 94 148 127 77 158 41 144 236
2025/20261.027 168 276 309 274 0 0 0 0 0 0 0 0
Totale 4.002